Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

SELECT Trial Investigators

doi:10.1016/S0140-6736(24)01498-3

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

SELECT Trial Investigators

School of Public Health

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	773-786
Number of pages	14
Journal	The Lancet
Volume	404
Issue number	10454
DOIs	https://doi.org/10.1016/S0140-6736(24)01498-3
State	Published - Aug 24 2024

ASJC Scopus Subject Areas

General Medicine

Keywords

Cardiovascular Diseases/mortality
Double-Blind Method
Humans
Middle Aged
Male
Treatment Outcome
Heart Failure/mortality
Stroke Volume/drug effects
Glucagon-Like Peptides/therapeutic use
Injections, Subcutaneous
Obesity/complications
Female
Hypoglycemic Agents/therapeutic use
Aged

Access to Document

10.1016/S0140-6736(24)01498-3

OpenUrl availability

Full text

Cite this

@article{f5416ef0c6ba4fbe93380f49df9ef884,

title = "Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial",

keywords = "Cardiovascular Diseases/mortality, Double-Blind Method, Humans, Middle Aged, Male, Treatment Outcome, Heart Failure/mortality, Stroke Volume/drug effects, Glucagon-Like Peptides/therapeutic use, Injections, Subcutaneous, Obesity/complications, Female, Hypoglycemic Agents/therapeutic use, Aged",

author = "{SELECT Trial Investigators} and John Deanfield and Subodh Verma and Scirica, {Benjamin M.} and Kahn, {Steven E.} and Emerson, {Scott S.} and Donna Ryan and Ildiko Lingvay and Colhoun, {Helen M.} and Jorge Plutzky and Kosiborod, {Mikhail N.} and Hovingh, {G. Kees} and S{\o}ren Hardt-Lindberg and Ofir Frenkel and Weeke, {Peter E.} and S{\o}ren Rasmussen and Assen Goudev and Lang, {Chim C.} and Miguel Urina-Triana and Mikko Pietil{\"a} and Lincoff, {A. Michael} and Mitsunori Abe and Abhaichand, {Rajpal K.} and Abhayaratna, {Walter P.} and Atul Abhyankar and Abidin, {Imran B.Zainal} and {Abou Assi}, Hiba and {Accini Mendoza}, {Jose L.} and Mine Adas and Agaiby, {John M.} and Agarwal, {Devendra K.} and Maher Agha and Azazuddin Ahmed and Petteri Ahtiainen and Elmar Aigner and Naik Ajay and Norsiah Ali and Amer Al-Karadsheh and Roy Allison and Allison, {Dale C.} and Diana Alpenidze and Yuksel Altuntas and Ayham Al-Zoebi and Roy Ambuj and John Amerena and Anderson, {Robert J.} and Toshiaki Ando and Robert Andrews and Elizaveta Antonova and Appel, {Karl Friedrich} and Serena Tonstad",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license",

year = "2024",

month = aug,

day = "24",

doi = "10.1016/S0140-6736(24)01498-3",

language = "English",

volume = "404",

pages = "773--786",

journal = "The Lancet",

issn = "0140-6736",

number = "10454",

}

TY - JOUR

T1 - Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure

T2 - a prespecified analysis of the SELECT trial

AU - SELECT Trial Investigators

AU - Deanfield, John

AU - Verma, Subodh

AU - Scirica, Benjamin M.

AU - Kahn, Steven E.

AU - Emerson, Scott S.

AU - Ryan, Donna

AU - Lingvay, Ildiko

AU - Colhoun, Helen M.

AU - Plutzky, Jorge

AU - Kosiborod, Mikhail N.

AU - Hovingh, G. Kees

AU - Hardt-Lindberg, Søren

AU - Frenkel, Ofir

AU - Weeke, Peter E.

AU - Rasmussen, Søren

AU - Goudev, Assen

AU - Lang, Chim C.

AU - Urina-Triana, Miguel

AU - Pietilä, Mikko

AU - Lincoff, A. Michael

AU - Abe, Mitsunori

AU - Abhaichand, Rajpal K.

AU - Abhayaratna, Walter P.

AU - Abhyankar, Atul

AU - Abidin, Imran B.Zainal

AU - Abou Assi, Hiba

AU - Accini Mendoza, Jose L.

AU - Adas, Mine

AU - Agaiby, John M.

AU - Agarwal, Devendra K.

AU - Agha, Maher

AU - Ahmed, Azazuddin

AU - Ahtiainen, Petteri

AU - Aigner, Elmar

AU - Ajay, Naik

AU - Ali, Norsiah

AU - Al-Karadsheh, Amer

AU - Allison, Roy

AU - Allison, Dale C.

AU - Alpenidze, Diana

AU - Altuntas, Yuksel

AU - Al-Zoebi, Ayham

AU - Ambuj, Roy

AU - Amerena, John

AU - Anderson, Robert J.

AU - Ando, Toshiaki

AU - Andrews, Robert

AU - Antonova, Elizaveta

AU - Appel, Karl Friedrich

AU - Tonstad, Serena

PY - 2024/8/24

Y1 - 2024/8/24

KW - Cardiovascular Diseases/mortality

KW - Double-Blind Method

KW - Humans

KW - Middle Aged

KW - Male

KW - Treatment Outcome

KW - Heart Failure/mortality

KW - Stroke Volume/drug effects

KW - Glucagon-Like Peptides/therapeutic use

KW - Injections, Subcutaneous

KW - Obesity/complications

KW - Female

KW - Hypoglycemic Agents/therapeutic use

KW - Aged

UR - http://www.scopus.com/inward/record.url?scp=85201638599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85201638599&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(24)01498-3

DO - 10.1016/S0140-6736(24)01498-3

M3 - Article

C2 - 39181597

AN - SCOPUS:85201638599

SN - 0140-6736

VL - 404

SP - 773

EP - 786

JO - The Lancet

JF - The Lancet

IS - 10454

ER -

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

ASJC Scopus Subject Areas

Keywords

Access to Document

OpenUrl availability

Other files and links

Cite this